MCID: SML016
MIFTS: 50

Small Intestine Cancer

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Small Intestine Cancer

MalaCards integrated aliases for Small Intestine Cancer:

Name: Small Intestine Cancer 12 53 15
Neoplasm of Small Intestine 12 73
Small Intestine Neoplasm 12 15
Malignant Neoplasms of the Small Intestine 53
Malignant Tumor of Small Intestine 73
Neoplasm of the Small Intestine 29
Small Intestinal Neoplasm 12
Small Intestine Carcinoma 73
Small Bowel Tumors 53

Classifications:



Summaries for Small Intestine Cancer

Disease Ontology : 12 An intestinal cancer that is located in the small intestine.

MalaCards based summary : Small Intestine Cancer, also known as neoplasm of small intestine, is related to gallbladder cancer and small intestinal adenocarcinoma. An important gene associated with Small Intestine Cancer is SST (Somatostatin), and among its related pathways/superpathways are Gastric cancer and DNA Damage. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include the small intestine, small intestine and liver, and related phenotypes are cellular and digestive/alimentary

Wikipedia : 76 In oncology, small intestine cancer, also small bowel cancer and cancer of the small bowel, is a cancer... more...

Related Diseases for Small Intestine Cancer

Diseases in the Small Intestine Cancer family:

Intestine Carcinoma in Situ

Diseases related to Small Intestine Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
# Related Disease Score Top Affiliating Genes
1 gallbladder cancer 31.5 KRAS MLH1 MUC2
2 small intestinal adenocarcinoma 31.2 CDX2 KRAS MUC2 MUC6
3 duodenum cancer 28.2 CDX2 ENO2 KRAS KRT7 MUC2 MUC6
4 intestinal benign neoplasm 26.3 CCND1 CDX2 KRAS MLH1 MSH2 MUC2
5 small intestine cancer, childhood 12.1
6 pancreatic intraductal papillary-mucinous neoplasm 10.9 MUC2 MUC6
7 tumor of exocrine pancreas 10.9 MUC2 MUC6
8 jejunal cancer 10.8 KRT7 MUTYH
9 small intestine carcinoid neuroendocrine tumor 10.8
10 ileum cancer 10.8
11 adenoma of the pancreas 10.8 KRT20 SST
12 chronic ethmoiditis 10.8 MUC2 MUC6
13 bile duct mucoepidermoid carcinoma 10.8 KRT7 MUC2
14 cystic basal cell carcinoma 10.8 KRT20 KRT7
15 seminal vesicle adenocarcinoma 10.8 KRT20 KRT7
16 transverse colon cancer 10.8 KRT20 KRT7
17 endocervical carcinoma 10.8 KRT7 MUC6
18 ovarian large-cell neuroendocrine carcinoma 10.8 KRT20 KRT7
19 eyelid neoplasm 10.8 KRT20 KRT7
20 malignant syringoma 10.8 KRT20 KRT7
21 tn polyagglutination syndrome 10.8 MUC2 MUC6
22 krukenberg carcinoma 10.8 KRT20 KRT7
23 large intestine adenocarcinoma 10.8 KRT20 KRT7
24 pancreatic somatostatinoma 10.8 ENO2 SST
25 retroperitoneal neuroblastoma 10.8 ENO2 SST
26 linitis plastica 10.8 KRT20 KRT7
27 lung acinar adenocarcinoma 10.8 KRT20 KRT7
28 sensory organ benign neoplasm 10.7 ENO2 KRT7
29 hyperplastic polyposis syndrome 10.7 KRAS MUTYH
30 adenoid squamous cell carcinoma 10.7 KRT20 KRT7
31 duodenal somatostatinoma 10.7 ENO2 SST
32 cecal benign neoplasm 10.7 KRT7 MUTYH
33 eccrine sweat gland neoplasm 10.7 KRT20 KRT7
34 microcystic adenoma 10.7 ENO2 MUC6
35 middle ear adenoma 10.7 ENO2 KRT7
36 vulval paget's disease 10.7 KRT20 KRT7
37 mutyh-associated polyposis 10.7 KRAS MUTYH
38 intratubular embryonal carcinoma 10.7 KRT20 KRT7
39 meibomian cyst 10.6 KRT20 KRT7
40 mature teratoma of the ovary 10.6 ENO2 KRT20
41 bladder lymphoma 10.6 KRT20 KRT7
42 papillary serous adenocarcinoma 10.6 KRT20 KRT7
43 cutaneous ganglioneuroma 10.6 ENO2 KRT20
44 encapsulated thymoma 10.6 CD79A SST
45 mucinous tubular and spindle renal cell carcinoma 10.6 KRT7 MUC2 MUC6
46 medulloepithelioma 10.6 KRT20 KRT7
47 glycogen-rich clear cell breast carcinoma 10.6 KRT20 KRT7
48 goblet cell carcinoid 10.6 ENO2 KRT20
49 renal pelvis carcinoma 10.6 KRT20 KRT7
50 carcinoid tumors, intestinal 10.5 ENO2 SST

Comorbidity relations with Small Intestine Cancer via Phenotypic Disease Network (PDN):


Colorectal Cancer Deficiency Anemia
Intestinal Obstruction

Graphical network of the top 20 diseases related to Small Intestine Cancer:



Diseases related to Small Intestine Cancer

Symptoms & Phenotypes for Small Intestine Cancer

MGI Mouse Phenotypes related to Small Intestine Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 CDX2 ENO2 KRAS KRT7 MLH1 MSH2
2 digestive/alimentary MP:0005381 9.7 SST CDX2 KRAS MLH1 MSH2 MUC2
3 homeostasis/metabolism MP:0005376 9.7 SST CDX2 KRAS KRT7 MLH1 MSH2
4 neoplasm MP:0002006 9.28 CDX2 KRAS MLH1 MSH2 MUC2 CCND1

Drugs & Therapeutics for Small Intestine Cancer

Drugs for Small Intestine Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
5
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
8
Ofloxacin Approved Phase 3 82419-36-1 4583
9
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
10
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
11
Morphine Approved, Investigational Phase 3 57-27-2 5288826
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
14 Orange Approved, Nutraceutical Phase 3
15 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
16 Amoxicillin-Potassium Clavulanate Combination Phase 3
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antitubercular Agents Phase 3
21 beta-Lactamase Inhibitors Phase 3
22 Clavulanic Acid Phase 3
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
24 Cytochrome P-450 Enzyme Inhibitors Phase 3
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
29 glucocorticoids Phase 3,Phase 2,Phase 1
30 Hormone Antagonists Phase 3,Phase 2,Phase 1
31 Hormones Phase 3,Phase 2,Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
33 Antirheumatic Agents Phase 2, Phase 3,Phase 1
34 Anti-Anxiety Agents Phase 3
35 Antiemetics Phase 3,Phase 1
36 Antipruritics Phase 3
37 Antipsychotic Agents Phase 3
38 Autonomic Agents Phase 3,Phase 1
39 Central Nervous System Depressants Phase 3,Phase 1
40 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
41 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
42 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
43 Psychotropic Drugs Phase 3
44 Serotonin Agents Phase 3,Phase 2
45 Serotonin Antagonists Phase 3,Phase 2
46 Tranquilizing Agents Phase 3
47 Epoetin alfa Phase 3 113427-24-0
48 Hematinics Phase 3
49 Renal Agents Phase 3
50 Analgesics Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Differences in Preparation for Small Bowel Capsule Endoscopy Recruiting NCT03351972 Phase 4 Klean Prep
3 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
5 Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy Completed NCT00003600 Phase 3
6 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
7 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
10 Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
11 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
12 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
13 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
14 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
15 Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
16 Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
17 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
18 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
19 Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
20 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
21 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
22 Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
23 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
24 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
25 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
26 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
27 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
28 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
29 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
30 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
31 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
32 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
33 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
34 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
35 NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) Completed NCT00248404 Phase 1, Phase 2 NB1011
36 Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Recruiting NCT02949219 Phase 2
37 Effects of S-1 and Capecitabine on Coronary Artery Blood Flow Recruiting NCT02216149 Phase 2 S-1;Capecitabine
38 Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Active, not recruiting NCT00416351 Phase 1, Phase 2 clofarabine
39 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Active, not recruiting NCT01202409 Phase 2 Panitumumab
40 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
41 Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine Terminated NCT00003522 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
42 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
43 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
44 Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma Unknown status NCT00562068 Phase 1 cyclophosphamide;doxorubicin hydrochloride;prednisolone;vincristine sulfate
45 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Unknown status NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
46 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
47 Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
48 Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma Completed NCT00561418 Phase 1 vorinostat
49 Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma Completed NCT00006009 Phase 1
50 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma Completed NCT00088868 Phase 1 alvespimycin hydrochloride

Search NIH Clinical Center for Small Intestine Cancer

Genetic Tests for Small Intestine Cancer

Genetic tests related to Small Intestine Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Small Intestine 29

Anatomical Context for Small Intestine Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Small Intestine Cancer:

19
The Small Intestine

MalaCards organs/tissues related to Small Intestine Cancer:

41
Small Intestine, Liver, Lung, T Cells, Bone, Breast, Skin

Publications for Small Intestine Cancer

Articles related to Small Intestine Cancer:

# Title Authors Year
1
Adiposity and risks of colorectal and small intestine cancer in Chinese adults: a prospective study of 0.5 million people. ( 29872150 )
2018
2
[A Case of Small Intestinal Cancer Repeating an Ileus Symptom Complicated with Refractory Arrhythmia]. ( 26805146 )
2015
3
Hemorrhagic small intestine cancer with solitary pulmonary metastasis initially presented as suspected primary lung cancer: an autopsy report. ( 18432067 )
2007
4
Associations between small intestine cancer and other primary cancers: an international population-based study. ( 16003748 )
2006
5
Small Intestine Cancer Treatment (PDQAr): Patient Version ( 26389461 )
2002
6
Small Intestine Cancer Treatment (PDQAr): Health Professional Version ( 26889555 )
2002
7
Small Intestine Cancer Treatment (PDQAr): Health Professional Version ( 26389423 )
2002
8
Small Intestine Cancer Treatment (PDQAr): Patient Version ( 27390834 )
2002
9
Risk factors for small intestine cancer. ( 8481495 )
1993

Variations for Small Intestine Cancer

Expression for Small Intestine Cancer

Search GEO for disease gene expression data for Small Intestine Cancer.

Pathways for Small Intestine Cancer

Pathways related to Small Intestine Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.02 CCND1 CDX2 KRAS MLH1 MUC2
2 11.93 CCND1 MLH1 MSH2 MUTYH
3 11.69 CCND1 KRAS MSH2
4 11.14 CCND1 KRAS MLH1 MSH2
5 10.62 CCND1 KRAS

GO Terms for Small Intestine Cancer

Cellular components related to Small Intestine Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Small Intestine Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 9.8 MLH1 MSH2 MUTYH NTHL1
2 cellular response to DNA damage stimulus GO:0006974 9.72 CCND1 MLH1 MSH2 MUTYH NTHL1
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.65 KRAS MUC2 MUC6
4 response to X-ray GO:0010165 9.51 CCND1 MSH2
5 somatic hypermutation of immunoglobulin genes GO:0016446 9.46 MLH1 MSH2
6 isotype switching GO:0045190 9.43 MLH1 MSH2
7 maintenance of gastrointestinal epithelium GO:0030277 9.4 MUC2 MUC6
8 positive regulation of isotype switching to IgG isotypes GO:0048304 9.37 MLH1 MSH2
9 positive regulation of isotype switching to IgA isotypes GO:0048298 9.26 MLH1 MSH2
10 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MLH1 MSH2
11 mismatch repair GO:0006298 9.13 MLH1 MSH2 MUTYH
12 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MLH1 MSH2

Molecular functions related to Small Intestine Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.58 CDX2 MSH2 NTHL1
2 mismatched DNA binding GO:0030983 9.37 MLH1 MSH2
3 DNA N-glycosylase activity GO:0019104 9.32 MUTYH NTHL1
4 oxidized purine DNA binding GO:0032357 9.26 MSH2 MUTYH
5 MutLalpha complex binding GO:0032405 9.16 MSH2 MUTYH
6 MutSalpha complex binding GO:0032407 8.96 MLH1 MUTYH
7 guanine/thymine mispair binding GO:0032137 8.62 MLH1 MSH2

Sources for Small Intestine Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....